RxDoctor Payments Data

Erica Parrotta, DO

Neurology · Albany, NYNPI 1275927303

Payments from drug & device makers

$116,667in general payments, 2019–2025

Across 331 payments — averaging $352.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$90K
  • Genentech USA, Inc.$7K
  • E.r. Squibb & Sons, L.L.C.$7K
  • Bristol Myers Squibb$5K
  • AbbVie$3K
  • Novartis$2K
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$10,8809%
  • Speaking & faculty fees$6,3755%
  • Grants$90,00077%
  • Travel & lodging$1,7441%
  • Food & beverage$7,4576%
  • Education$2100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,667 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$62,455
Medicare patients
110
Services billed
5,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZavescaMiglustat12$399,027
Kesimpta PenOfatumumab32$276,409
Dalfampridine ErDalfampridine183$133,709
TecfideraDimethyl Fumarate11$97,884
Teriflunomide40$80,045
CopaxoneGlatiramer Acetate11$69,506
Nurtec OdtRimegepant Sulfate17$26,078
NuedextaDextromethorphan Hbr/Quinidine14$21,178
UbrelvyUbrogepant17$16,985
QuliptaAtogepant11$13,839
Modafinil95$7,337
Baclofen249$6,432
Gabapentin288$5,460
Tizanidine Hcl116$3,282
Duloxetine Hcl34$1,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonZavesca$143$399,02712 claims
BiogenTecfidera$90,438$97,88411 claims
Teva Pharmaceuticals USA, Inc.Copaxone$149$69,50611 claims
AbbVieUbrelvy, Qulipta$3,328$30,82428 claims
PfizerNurtec Odt$18$26,07817 claims
Upsher-smith Laboratories LLCTopiramate$17$76738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →